Search by Drug Name or NDC
NDC 25021-0128-67 Ceftazidime 2 g/1 Details
Ceftazidime 2 g/1
Ceftazidime is a INTRAVENOUS INJECTION, POWDER, FOR SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Sagent Pharmaceuticals. The primary component is CEFTAZIDIME.
MedlinePlus Drug Summary
Ceftazidime injection is used to treat certain infections caused by bacteria including pneumonia and other lower respiratory tract (lung) infections; meningitis (infection of the membranes that surround the brain and spinal cord) and other brain and spinal cord infections; and abdominal (stomach area), skin, blood, bone, joint, female genital tract, and urinary tract infections. Ceftazidime injection is in a class of medications called cephalosporin antibiotics. It works by killing bacteria. Antibiotics such as ceftazidime injection will not work for colds, flu, or other viral infections. Using antibiotics when they are not needed increases your risk of getting an infection later that resists antibiotic treatment.
Related Packages: 25021-0128-67Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Ceftazidime Injection
Product Information
| NDC | 25021-0128 |
|---|---|
| Product ID | 25021-128_e78f9899-2616-425d-90d3-9da00da1d708 |
| Associated GPIs | 02300080002117 |
| GCN Sequence Number | 009172 |
| GCN Sequence Number Description | ceftazidime VIAL 2 G INJECTION |
| HIC3 | W1Y |
| HIC3 Description | CEPHALOSPORIN ANTIBIOTICS - 3RD GENERATION |
| GCN | 32352 |
| HICL Sequence Number | 013429 |
| HICL Sequence Number Description | CEFTAZIDIME |
| Brand/Generic | Generic |
| Proprietary Name | Ceftazidime |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | ceftazidime |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, POWDER, FOR SOLUTION |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 2 |
| Active Ingredient Units | g/1 |
| Substance Name | CEFTAZIDIME |
| Labeler Name | Sagent Pharmaceuticals |
| Pharmaceutical Class | Cephalosporin Antibacterial [EPC], Cephalosporins [CS] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA062640 |
| Listing Certified Through | 2022-12-31 |
Package
NDC 25021-0128-67 (25021012867)
| NDC Package Code | 25021-128-67 |
|---|---|
| Billing NDC | 25021012867 |
| Package | 10 VIAL in 1 CARTON (25021-128-67) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL |
| Marketing Start Date | 2015-07-01 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |